Testing of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacy.

ABSTRACT: The immunogenicity and safety of three novel host-range vaccines containing deletions in the transmembrane domain of dengue virus serotype 2 (DV2) E glycoprotein were evaluated in African green monkeys. The shorter transmembrane domains are capable of functionally spanning an insect but not a mammalian cell membrane, resulting in production of viral mutants that have reduced infectivity in mammalian hosts but efficient growth in insect cells. Groups of four monkeys received one dose each of test vaccine candidate with no booster immunization. After immunization, levels of viremia produced by each vaccine were determined by infectious center assay. Vaccine recipient immune response to wild-type DV2 challenge was measured on Day 57 by enzyme-linked immunosorbent assay and plaque reduction ne

SUBMITTER: Smith KM 

PROVIDER: S-EPMC3516330 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature